NASDAQ:PYXS

Pyxis Oncology Q1 2026 Earnings Results & Report

Pyxis Oncology logo
$1.44 +0.03 (+2.13%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.53%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pyxis Oncology missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.37 versus the -$0.35 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Pyxis Oncology EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Pyxis Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$19 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Q1 2026 Earnings FAQ

Pyxis Oncology (NASDAQ:PYXS) reported earnings of -$0.37 per share for Q1 2026, missing the consensus estimate of -$0.35. The report was announced on Thursday, May 14, 2026.

Pyxis Oncology Earnings Headlines

Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $7.00
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue.

The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.

View Pyxis Oncology Profile